This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AMRI Promotes Susan Collins To Director, Business Development

Stocks in this article: AMRI

ALBANY, N.Y., June 17, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Susan Collins has been promoted to Director of Business Development for North American Discovery Services, reporting to Christopher Conway, Vice President, Business Development. In this new role, Ms. Collins is responsible for leading AMRI's North American Discovery Business Development team in the promotion of the full spectrum of AMRI's global drug discovery services. Bringing 19 years of pharmaceutical industry and leadership experience to this role, Ms. Collins will manage AMRI's North American discovery business development activities and professionals and spearhead AMRI's efforts to expand discovery opportunities and business within the sector.

(Logo:  http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)

Mr. Conway said, "Susan is a top-performing sales professional with a proven ability to drive territorial revenue growth and increase market penetration through exceptional customer relationship skills. Her track record since joining AMRI and prior leadership experience position her well to be very successful in this expanded role. I would like to take this opportunity to publicly congratulate Susan and wish her well in this new position. I look forward to working with her more closely going forward."

Before joining AMRI's discovery team in 2012, Ms. Collins held roles of increasing responsibility in sales and leadership positions at Organon BioSciences, which was later acquired by Schering-Plough and Merck. As Region Sales Director, she was responsible for leading award-winning management and representative teams in the promotion of CNS, cardiovascular, anti-infective, anesthesia, pain management and contraceptive products to the medical community across 28 states. Directing teams of up to 125 employees, Ms. Collins was responsible for generating sales of more than $174 million with a $7.8 million operating budget.  

Thomas E. D'Ambra, Ph.D., President and CEO, AMRI, said, "AMRI's business development professionals are integral in creating and building long-term relationships and partnerships with our many customers. AMRI's discovery services are complex, cover our global locations and require customization of offerings and solutions for our customers' specific needs. Susan has demonstrated an innovative and ambitious approach to building business and customer relationships since joining AMRI in 2012. We look forward to working with Susan and her team in building our North American discovery business to the next level of success."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,196.19 -191.02 -1.10%
S&P 500 2,001.66 -27.89 -1.37%
NASDAQ 4,637.78 -43.7170 -0.93%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs